HUE032539T2 - Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására - Google Patents
Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására Download PDFInfo
- Publication number
- HUE032539T2 HUE032539T2 HUE13704171A HUE13704171A HUE032539T2 HU E032539 T2 HUE032539 T2 HU E032539T2 HU E13704171 A HUE13704171 A HU E13704171A HU E13704171 A HUE13704171 A HU E13704171A HU E032539 T2 HUE032539 T2 HU E032539T2
- Authority
- HU
- Hungary
- Prior art keywords
- hogy hogy
- ija
- antigen
- hbsag
- vald
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Description
ObÉÜii&s&fs
Ittekvesikm rsfstsrW toli Si «aleae© thmsisdhf'# Ü* htfpiát i ik\Bs&^mé*yMömi%>h!lm tyiumgmtyp® b vaienvs. ttmd&dttg of its <s«j>sal8r:^i^m«Wd«, called piMytiixisylsMöi^hm^te^R?), whifcb iapi« má&r U> he eifceUw w children t»tdér eoigagated mmmísf fawtein* fbrexmspk the tmimíjfre^is&í·· :&bh samfekstjosss ^ífekpssMi^sá^ls'^iminiaimfclfe ynnag ^Mt^.gei^^^í.ew^ÉgíiS^K^.sa^tg^ís: that «ifi :i:pi?ssi&k dó:ysesstsaíd spfest s&vsmi diseases its a skgfe oixsaSion,. ssiá stísss as aitimbmimbssss! adjuvant. iíafest apphítatkísis WO öabfObM5? sxmcems ihe pí<?l>iem oí vsomrc stsMIÍty ami teeomrooíKlst wh«a the hepatitis B arttfps is |MW%. «wtál^^^feg-tí öto stifcimlsmm byimside; & is reeofmsemfei! is a<fesri H mm iiktmimmM0imyphm^mk or tust k· sdkssb b<
Pmmú appiiestot WO bWíSBCib cilsckíses a vaeeme eompossüon eoinpmmg, as k dssmhtd ott page O, antigens sifepisg líspstlls:© atsd ·%&βι»ψΜίΜ -i0mmm type b te 1^ sáyoilssásRfe ss sltsmtotn salt is srder P> & immsmogsiáis 'fhis is m: patt kkarifte ew:«itfe"8te Itepatkk É snrtfee anipn nrMSs Ag. ÜöWever, ss. is indicated sxi page 1?. of application \!!i$ö 9WK19Ö6, theiöih váláséit.. consisting ísiiiKe t^pssíiáF .pi^saccharklí txmjngated to ?he fctatsus proton, has a fandeaey tn io« its intmranogeaistty over time seben «is aliboBkíd onto almntnutn salts. 1« order to avoid thss drawback, the solution proposedtutilig prior art p asistd stsstady beets tecomtstended is the prior applies boti K'lVFRyet-'OÖ79I, to add anions aodiioípaftístdiaí ydsophaíe,; «ssbösale «a'ieltfsíe isssi: ítevvcr, tbc athbor» sí the present inveftiibrBin^toed üks!* khifedői»· addition of nms* iniprtiaolar oi: :phssphdtgs:pteersa?to?yiiísf atnsaiiy mak«&i|:pössMfetö ps^vesttítheisílissppíiíts of tW-'í onto atomimat:! oKltSd hjnh oxide tAHHJHt. and sheredtrrdb .; maintain ii'1»«hrtí||^My'Stíy#atm«. this addhs^sÍj^vfe»S';''ÍÍ: terhsek of desorbmg the hepadris B sutllee autfgsst syhsn itbe MerflMt. fc<*lf. also hepp nisoihtd m®. atasÉhdn oxide hydros ide ftklkereíbrc necessary ts üsd a method tor preparing a vaccine coobbsiaiam csmspmhig nímiuatrm xixlin hedroaak so wlneh tt\ tiocxn v* R sbiHu e .-unpoo >*> kor 5 nhmtxd 0¾ xkiOH. ohxie.'S:dmBti> songén tg Isspí: ssmiKigmbed. Ίο this end, the subject <>i the presotsfíftsvaáitm: Is s:isethod for preparing a Snpttd vasc-ka esmbibsstlsn .Vv'tüptts'ngai least • ooebepatltss 0swtface^.stspesstUBsApi -.,· «»- ......—ππ:·ι·-·ιιΤΒ'ΐ8ΐ' - one /íi/Swwroe Svíx·. h (Bib) antikon eonsktiog of capsular poiysaecharsde XAnXgsted nt a cntrier protein. - aiunnmms oxide hydroxide (AiOOSii, la which tbc hepatitis B sártök anhgers te k«^t ΡΘ£Η| .$§: i$ ffitpf nonadsorbeds wherein: - the hepatitis B sorfa*. a antigén k adsorbed onto ÁH iOt t aj order to obtain ao AlDOH/HBsAg ίΧοοηΙον, ::» sasd AiOOiidlBsAg complex is mixed wish the Btb antigen in the presence of caskmtc otnirto add» «1 a vo>\'«»th»iO - <.H &s teást töd ,ng I aad or phospoak κ n. .a a concentration of' s^ >H mMoi i
By 'íátoe of the method according to the invention, n k po-jdbie m achieve he desired balance ix iwe*. n looping the aasotption of the hopatUix it surface antigen on sire ahntsintsm aside hydroxide anti keeping the ixmmiiOr-pfh'O of the ihh <mm\o
According to one particular innhodhneas of the inventions the SiBxAg sohgars 1st adsorbed onto she akinlmiost bp nevnx ;'s 'itvrn.o ' r»f AKOB wxn ' s,ím esw »n of 1 B \g vor -nsta'g tot at icost 4 f»\ i' ptoterabh sttkwi 12 honeg preferably between 20 and 24 bonts,
According to one pamcuh» embodiment of she invetifiou the: etsijpslc asnlpp: stkidv are added.....to saM
AiiXIi'kXiBBAgcotnpicv before the mmag with the Hih antigen,
According to itt· aítentaítvecmhoái»^;iM^|w#^^^bfilc ssntösvtsdtdkWstktó topáid Bib antigen before She mixiog with the AKX>lbB§Ai|§ebtpgte
According to doe ftplmdiment of the ipphtiöö., ||^ phosphate Idas aid added ;Hfpi4ÉI^C^^Ág coipptek before the tnixing with the Bib antigen.
According to ppg dixtbrsdimem of site invention, the pH §f|^f:VgrP£>ipM^ sskhpioXhl the ÁlfhBfÉBSsAi complex k adjusted to 7.1 ·> (s. \ before the mixing with the Ihb antigen, lie subject of ihe: Ihvciihtn teteit ipcfPOTöbfesöMi id the snethod efahsted and conspri?;i:og at least - the· hepatitis B sortaco antigen» - the diphtheria antigen h the form s>f diphtheria toxin D, - she tetanus not igen in the fetid of tefastss tnkin T, ' die whooping coogi; antigens in the form of Pmifisd InsinfPfvd) and of Rksmentons Hemagghsttmts (FHAy - She Hwmopttilui Og/ocoroe type:h gntlgest> in pk«tphsík..«ö»iti^y-:-to the teMRos protein (Rif- 14> • the poiio antigens tit the form ot inscitvated type l, 2 amO vimses> terds íí: vatxdnP ípornghyjtsóh hte: thé stttiMli* öf Bájtig SS tlsslö: 1ss?sS: SsfefsSV: axdidmig Q|56;^Hös:ss: Is iíökö >%ψ xfhailyttpbtlisate. 8 has prove» to be teteietstly xtutsle to rem-iks immunogenie nodi bx·. buy sí iiw^iswii st> rrsstes after its date of msssaf&cttire A««*^3Rg.--to f§&'.vaeted pomflositioa comprise* a Ixepatitis 0 mííükí? assisges-s tsRSsAg). Ibis tetgds:r sssry ds prtetsjar be a hesteteB tette antigén ste as. tlw »8« present ws the Reoosuba»:·. HB** «vtódssá* teío assy pite hepatitis B teteé. b may is* partiadat be the reeombusaht: tesgnn entajoed by tteseisisstte xsf §. /termrte />ís/mi»fte! yeast which te tens nsxtesexl, a<-.«. s>í-.Hf v κ» she texbosungy teteoped by Crucall, ssseh as the ssrse preste in she Hepavax-Gesste voocte te stse purposes of the teteson, sSe .smooth of HBsAg present ás a 0.5 mi dxaasis sdvansoge-oasty stexveess a üshI i:> kg: abá is particular iö pg ,,Actor<h«g to she invention. the vaccine composition e:í>s«peB«ss S type fe iitib) antigén. 3 his antigen consists of ds« esspsste polysaccharide of she hae-terimo or lteysteo*y3Rit>iud Phospte* iRftR) umea s-< μ.'!''«'\ΡοΡ h« a smu< poneO 'he x.·«*ser psote srs oho S'e an* sutesr ,*sed os ttv- respsxt as te teem* flékl 3s tm> he, tor example. diphtheria toxin t>, isipMsis f, i.iaemophihss s^hemaa lipoprotein Ö, CRM 3 $7 ra she Λ?, meningitidis outer mombrane protein (OMVl Use *s preferably made of the ivtams* pi Site isi teles- tetette the PRR-T etette, fdf the ptesBgs MM® present invention, the PRP-T conjugate .:may be present in a proportion of from I to 30 gg of I-RR ptedJ ml dose; advteággteliy froth 5 so 2b up ol » per dose; preferably from 30 m 15 p§ ofPRP M.1»: dE>se} end more pamctdariy t a pg ot i'S ib conjugated to 22·· 3d gg.-oftote«s prs>s*sn.
Afeordlbg so she inventsos, ibe vaEC*n6 CE>mjH>5«i0S! cotnprsies alostsisusm oxide hydroxide ARK-Bi ihss idssptbssMfs Stv.< (s Eortmnís3s n«.<'nc%.»S* v^ilc-uab»' 'ixdts'Xtdc tu.v \RRds srbKis oats bo sisód kss-te fgis'posbb i-is'jsse pressnt inveinmn m&\ be, idr example, the ΛΙΟΟΗ sail sxsRI by Brenntag AO, or R«hydrage3 |is \ i»os >·. h ivn (Uj^ies ><te' '·< Μ» eísK'ug** tb, >"i^ vd oi f \k tsxs' so v,sxh κί he two adjuvants diffets. l isa asnoant of AbdiH used is csüatlated so as to allow a satisfactory tsnmyne response us be ssehkrxad; ;s depends.:tn parsissular ess the nsnstbei assd snt she nature ot the sssssigetss ptesens in the tomposltldu end also on sins amount of eaelsiofthsms arttfaetw;· sb-sresy by \v;iv of suformanon, the oíSsíoíSos adsorption ot HBsAg onso Λ100Η is 3brass pg ot ps'oseas per sog of alnniiinssfs teorsviOititBi-idy. ihc arnysint of Atr.)OH ss expsessed as ararasiv; ot aluinininn AÍ s bof a v.;.'viS;> sb'···' í '''.ariis.a ' :st pe os'sss3'.s^ aba-^alae\ other sddit-ossei a-usp.esss, s ' pg os yjonuuent u<'sssd sees liSidVne ukius· a ,n> aniossns sSaP i: hesxvever isj4ufteii.'nt so «obtain the dessted ett'seaxy vvheo oshes' sasi gens are ssddeb. Thus, depersdiug oss she ssiktisiots of one or issrsos iutsSitisusat ansigxau. IÖ ng xs? HBsAg stay 3;e btoujdu stssx« aonts,; x« s«s« isxxssi 0 OS nsg So 3 mp xo siítanntotn "·χSo, Is o. OSx' ssao -usosn .sinosoa ',e,x>tranx teas by Shi itepfeatSi |íhsrts8és>te la s
For o\.mspk, « d,5 ob dose vt a gr 4' <ts r ^\s -e \ oevpi ssnrg diphibo as ses mm . OrfKOptm. o»ttí«ih ami mpaUOs B ; v ííís- mm m '.mioo' ath n óm s - ».' sí; y os am hí ο, p-o >. okik ayrm s‘sm.eh dt> rm: Ά aluminum.
According to the sttvontion, the hepatitis 0 «.urfctee antigen is kept a-terhed o« AKX>Fi, which means ihat at H:<ssí 60%, preferably at kast *5%, preferably as least ?U%, prefer&hiy at least 7$%t |>tefcr&bl>- at kast 50%, preferably at least %$%, preferably at kaas vo*·,», preferably at least 9$% of the total amount of this antigen preseat ie the composition is present so adsorbed fosat.
According to the invention, the Hlb asdigen is kept nonadsorhed s.>n AÍUOI1, which memo. that at least b5%, preferably at ices; 70%, preferably at least 75% of the total amoaot of this ant ige» present sís dm composition is : presentin nost&dsorbodifhrrit;:
AuvOsJ-ap to she s os'so.o \ the period -Ί isme do* mg tv Inch hemmtss B sut'me osrí.v i is k>.pt s^otboo on she Ahkdt ,md tie 'tsh ontigut is kpt normAm he J se si leal 1 rc»x:h*. os e feral'v at kist A month , preferably ai least id nnmílm, prefemhk- at least 15 months, preferably at least .M month;,·, more preferably .0 •east 5b months start sop. fo>:o the dale of ιοηποίΧιοπ? of the composts ioo, o so··!', the storage- temperáimé ss 3 e 'X 1% „«abb lm Oil s sb'ski* is i ί e set Kd tt s>gei e ts B.be os O' S sue hm s s> o si ' ' *\ provided shat o remains onhin acceptable Homs i'kus, svhmi at least >555« of she tótat ásnom** of she IfRxAg present la the composition ο adsorbed on the AlUGH for 3 months starving from the elate of rmsmbiieture of she eomposikots stored at a temperature of 5 > 3Ό it is emirtdy possible that* after eme year arat still raider Pm xamv stoispeeshdiiiotis, 80% of she: total sipieioal: Of the HBsAgpfessm in the composition is kept adsorbed. io order to assess
Wish regard to tfeb siefsrrmissatkm ot sire percentage adsorption of the HBsAg. it is possible to use a swittakh 5 11\\ 'oeih'O ckomime s % ό d oied b·· ilv i οό'ν< « pixanaeope 1 3 ! A-χ-<1\ o, HA v> > ,φο,οΐΐ' 'Sin ÜHxAy p.i!-are O'Oses un,* ü i'u't O' LM >p, u weih o« « Am'I pan* loo HO-it s.s.' ssoiid ín <.oök'il with an ^oií-HBsAp seoesadar. monocli>o;-J aelibody, oilgG type, which is itselfdeierled by means of a peroJiidase-eonpierl artiklgt.» polyclonal antibody. A chromogeriK·: substrate lor peroxidase, íeirsaiedivlbosi/idiar t VMB), ^ives as a {Sevelopom egem. When st is added. & color develops the tatensity of usooh i.i proportional so dm aoiomti of lIBsAe captured m the oeli the ivsoiis ore simlyaed accmsfing to she p(o.díel Iοic osotisocl elesi-nbod no tbc 1 uropean ptsasnmcopei& Ihe pCKOougc adassrppon is öblhlPsd tan jise déteirsiiaalioíi of the tsrtaS HBsAg content mxiof the nooedsorlxal MBsAg content.
Wdh regard so she ammon of iK-soidsoBjed PdP- i the evalaaluxs can be earned out by ilPAl.-C-PAf1 (Ibgl*·· perfostsiaiiCe ion exchange chrorom-xgrophy - piilcsxl amperonk-irii. dettetion). x.,uiobog io ok-mcilonl vd tlx m\,ntiosi tk hepatitis ft i<mfmo anngeo ο. ,ηΧοΠνΒ onto bíOtílí Hns stop caB he carried oot by bringing the hepatitis B mMm aotigetríioíl iho AiGÖH inks contact to ibe abscsice of aoy „íher atóiprn ami allowing tóé hepatete B snsike nemem to tótónh mito tee AiüOH for o lenit 4 temt>, pipfembly s) Seató 13 hem's. entnoiy preiersbly betweee 20 ami 2.4 boom, m m< i& okain a preparation i^mkmg m AléOM fiságeMgieió Ibisvafefpím «tói tó mrtM'-&tá, -.seeing tó tóé tósotótók tó ;fe atóeace; of phosphide fees, -14¾ objective pmaeeó by mosna of»|5fö!«í3gí;d: eotóbeí ime betgen the hepatitis B suá&«r:«tfifes -ától&* : AfCTÖli grists:.·tó másMisiig d«íí«mtóffc Mmmíímm má tó : jtmmsf mg- #4 e laíetmtóos* wtótdt mn ihm rmiii tó wblíSBmsg,
Aseerdtegm ífe msíboitóf itó Invtóttóth tóé AMMWisAi Mipsat tó mised with ttó tílitsmftjftm 1» tós pnesesestófésífímiéami^iB acisfe: ásd or|tóosphafsJíss&.: Föf tóé B«n>osestóf dtó ac«fc!i is. mtendetóio mm pHi is tógáé? tiuí« die giii of4lje-v»^te-eo^e«»tí«9»;^á'í3wfwch will therblfeee be sv ctóí<wtó IBssa et tóe pfiöí üie..v»ecine. these esc ile partteyí&i Lyshte (Lysh Argmioe tArgt m idistiddis (His)· eseh örtóe^tóídhe iscids SiSfhtó-UM* n « i t nMm mt < lepi .ills ‘ Ve * i- He \ > |i\' ^<|. 'W*Vl? U'i * Vg íHis), Aecorbtóg tó s»te:pÉltófcmbtó|«»nB the eatksm·. smims ssids may be assobiitbd tó tósseptóeMm,· 'hlemtot*:«y :faÉfediaHy be rnsdb of die dipeptjdes tys-l.ys, :%s*Aíg. lys-Bis, Arg-Aíi, Idsd-lis.lltó-bysemf H»«At& Alfemaite«4y; a dipepbde of i^elsrthe poroses of the presetó fnsetóitm stray tó *m$mé. alfa sísdohte «Imi asdb mtd of -est sísefsafietó^iesi seki sefetóed fftóv Áfa, ¥sf fka Jso. Pso, Me| Phe. Ίφ, Oly* dog Tht, Cys, ϊy>\ Asp aod xa»öf&^::b:p^c%-»:|»^pmba:cMtó}i%;:«^*»ss»«-5aid^x ammo etid^s) in hoc amfor dtóeptide form may he esed. it % sf^i jmsslifg iomse stótóo setd timpomíiötss ;. isnps n '> o sn on, »iiJ » PtNoeriiam» « >*»» \ »te-wtáttmer:Mgfe;^^ifestó«^idptó*Re:: .too gr*a? a drop tó the pH dóriiig the addídsa efthe ammo acids,, i? tó possible is etiviskssi ímMsmg the pitóf the prepamtas eessipHsió|:4hesetd:tóo imíbtóbemre adtlsgiift tó Ató Aií>Of4d4B$Ág eompteig by msaes of a: base, ippt$i««fk:RidiömIliyiáro,Kklaí:.: Áeeoídsny to theloveotiöip: íheiemostóiAjfissttótae atóöo ittóds dlffssMdeiy pt^^f:.ötil.te;-:saoótego«tpas^öíV modi be iít teasí iCiif mgli*ptótóastggsousiy m fetói; lööisia^f,; iafcoiaf^^^váti&así Λ mgl -m«é& prefemldy at te-ast lett otg'h Them itittö'itófitói:masifeöm-i.dose,-.;Ö«wam^I:i:%pdlM6fe feritei-:«tax8fi«m .«tnornit to lx- at most 4 mgtóth more preferably at pmsl 1 .οιο*«:ρ?«Ι&»%. af:-te'#!S' #00 jtgfmL eofbtdy pefembiy at snovt TOO ngdtd. \bhsm caiceiaaieg ihe aotoodt of ctómnlfe ámító acids toitó added, the oafteale iBbteo acids that >sm> be iaooiitKvd by the media it·· •^Wz:iWm\$’m:®Ém:· then SiBsAg áed tóé Hsb aot»gett nresceS a tend d in· mlu-o ode ^ocooati iAecotding lo a,ne sitemabm of-the 4«íÍife«»ÍKt-;fc-aws^d: #í tókmte reiative to the weight of she fiib-.eo|tó^ar4tóÍtel^3«.^-1«.iP«5fltteftó*11ih-:pi|p^«ia^iÉctó<tótó'tó?tó:
Otód vuvht f OiO ni ! 4 V 1 5«tó ο>Κη»ΐ<'<νοι«ιΚ of ϊ Bitot ftg pjeternbh ot 1 l>tot t,0. or peatn obi· te iprok-raidy of i. id isi I: Jo or 4ii<
According tfa Ihe method ofthe ktvsklbsg imAliKiBTtBKAg s^misls^ ila ^^^^wisSs t^Afib sndgertd&Afes pmsmsi· Mmtikmfa tmtlito ««Ids, 'bt#sfe« fa sCpe^'»ta.:íi»»i AesmsAg te Qrs^sH&mdímet» «£ Ι^ί^Α^ν^ίΑϊ^ϊΟί^.ΙΙ^^χρ^ΐίκρ^^ϊίί-.Ιίΐϊ^ϊ;: isr« :Jíiblg-b ;1:« tbb: A10ÖI ί>;|· 1 ϊί 1¾Atg: <ϊθΤ5ΐ|?1«5ί bieíbf« SÍ: ís |>^Kíg:h3?íίΐΐ wíííΐ :fc>lí!b 2jÉ%^jí:.:T^-:^tepto«4e!«s «a^rfe-b^npNí fee sss4fcw:ftssÍR»g«8. phosphÉe $r :píbsiam;l^áf!^|es phosphate, t«f ehmrrtMure öfife tw 'Wmmmmt of phosphate: tons is calndnlM so ihsi i8ie.:«wla5«myi8ísoam of hepatiks B swd&og muigens reread ajilösrbud ok the AI£®| wfeiie at the Sasié lipid avíiding fe;atfeurpiion of the H?b tmigpn, 1¾¾ atwmnt vafiss; according to the auilgeos pr«^{%a«é'in particular atoetdidgipthoaoigoss otfeorthao the lIBsAg asitillífe sdtipös.
Thus, u>r.a':vamsvs oimihioaiios com|>mihg the aaiigens ppratalljr »É^1ó,p^^^-íKtóá^ ihat Is 1¾¾¾¾ id addition to. Hg IIIsAg and tiis W^nfegmjjEfee.^jiltiheria, tetany and whooping cough antigens, it titanic adyamageons to add phospbí8i'$É|K· -mfaiMgá tbt..phosphate km eo«eot#af|t>a Is the vacehie compfeslÖöft' íölimatehs obtained Is at leasi egoa! to 35 hthfoi/'k gob «wre particularly Is hetvveea 35 &ικΙ4$ mM«1/l< hlhjis uncladed. ptvíeraidy betweea digltd 44 mtMbl/h IMIis kichided, srtitrdy preferably between 38 and 42 ttlMokL illMlis Included Wording to ood igrefeshk) eutfeodknem, the phosphate loo . ermomitcaison In the vseeidf family ojklrmed Is4d othfol/k
Apsordtng to ott .omniatn > "if-' '«htrem, «he px> phate mm an aided m-tm amount »uoh that tfrc\ ate p*e*e«!
Is the vaccine composition «t a tmal eonecaif&tkm of jkdwssn 35 atsd 3S ksMPbk hokis included. This, ip «ipleted |>y uko adding «.athonote Ions, but in a limits M0MÍMMS&Í idee it has in íaet lkam SpWdbid: an excessive amount of c&thonate ions Is ufdavorabk. Advantageously, they may be added in an «.mount such ο η '\ \ m- present ϊ' te vaccine so* 4' "'>'i<n, ht> d <, veer’ruttoti ot loss than >« «-'gnai tu Hi m\kd i
In shock etdeh could destabilise the HBsAg and promote desinptum thereof, it
Is:tm*wtigt«feá lörftM$fe®:::$feö$ph*iu· ions η» several «exampk >n 2s dsstmet operai iim» tsteps). 1 feus, the phosphide kmsfsmtiy:lk added M st drst ooemtion,. I» a η.οιγ wl Jv ^tLis t p »' e to ae u \e a <nl mmmkfami of between 3$ timldO PtMoh. ΙοηΙκ Included; then, m a secood operaion, in an amount a huh makes ífpmsifelelQ-aeMfesfS^lrsáfewteieniiríttjeh 4 s specified dbbys:.
Acsordmg te- one, preferred emfeod invent «ft the- method according to the us yen; loo, the nB of the preparation oosa not s t 'do tn Jjusteu to 7 t + ! t Hostgtm Mn nogs « λ rh th« '5k4'tBBI"\> « > pies It has In fact been noted «hat such a pl I vine das a positive effect on keeping the Bin antigen in the nonadsorhed state. áecocdiítgto omipmu-'olar embodiment, the >>! i Is in addh Inn adjusted to ” I ± 0 Í a*et «he mo. ng ph^ce llnSj l%- vtttye of the meahod according to the invention, it k possibte to ofetalt» a HKome v»v;nposkioa in svhteh: - t (I; feast 60% <>r §0%. preferably as least total áSMstmf of (he-:i^iis:fö-:spte^«sii^ pi'CSOSt; fit Síi? vOOspOÍJhOSi H Uihorhfcd OSt Üfe AtfOfiHfeír Pf feSisi O SS!S®!S StSítíítg ÉtSift: Íli8 áate oí StOOiohí-Oni. <d Ú!é eOOspO'öSiO!! SÍOi vd .>S -.; tOüSpeoidiK' OÍ -'' i. 2Ά S -hid :||1| as jtefesí d$% ?ö% a- 711¾ %i:táiát:::8»tötó· ö$ Öfe'Hib·· hsoörn enmpöátfp ia nai sdsorhess os sin; A ti K dl tfe expresssoíí -‘AlOOt l/t l*UAg e o*tó<*·4 shöhlífbe sníeq:5Föíí3íÍI tiS intessí5tlí5¾¾ ífeö «|>íe?s s*s aifétó
Isti HBsAg antigén adsorbed on AKXJM. The antlgm^sitál^ ÜaÜ ksptólbá ar:: ttot.
One or snoro aíldsíiooíd antigén*: t»ay :-'m. srfdiífeo. &m® t««« iSN«:..«o^>fex»· -Λρί staff «5 psssiferdfef te diphthem sóstóid fi», tetanus tötóá-fí)* eoasé itmaííalar aiti|em «tó lstef«xifies* ttóa tPTxd), isfesssessfoíss hesmgglsiinín (1 H ferfedfe φ Mit antigén) aná *^Mim>®em •(ftmhtínO of mit. *a«n bar* s .«tat, leetóÍRg;%:« p.assvui.jrfy aásssatagoíías ssnhodisseoi D* -)¾ pfxd sad VfBÁ tustigenis rosy 1« addod 10 orá^::ts-.femHfe««titJ5itex< 1 he additional ^m^mm^-bsmiSMá iwmémi-w%y& ss^méU%Mbmíng öté htptóti ti isisen aasigvss preadsorbed ti) eisher onso the totói 8m<aost of AÍOOH that needs to be present so ihs ymdm cotnpOMtioa; (ti) or· -otó ·«,parisa)s8ss«n«8|·.-:s«^^|»!»»If-: tóid ίο M rtmh $m tónl. amottni, hifensasstely. tik- additional astslgvs» may he adsorbed separately, mit onto a parttal atntnsnt ed AiOÜH jnsl d-.v she BBs.Ag. A mixed adsorption- grocer may also be provides! ibr sosoe aofigens belssg advorbesj •anmrateK other.-' being #sosffecd xe^atóilly. V>v v k mi wt ukt votaodutan m *»<e o^etltró^mdlinidoibe-'áavtóto,. .-Sifted a dor site addition of vacis ssisitge)».
According so one advantageosfe etoifeénntó* gsyenoniy by w&y of exssnglih the fiiisAg ss adsorfesd sepsnstdiy onto a partial amount of ASOOÍi pra^ai ;n the final composition. fit panidof fho li> astd:l' assfi^iis as« septófelíy adsssfi^ noio she gdtfAlosta! pass of dse AiOOH. The HVl arid TMA -whiacplag aoagfs snfipos ars ttes a^fed to she;:;pr«|^mUors-t^dMmhi||: she AKX>H-lvr vo»npfex. eaeh of ifiessi two ndtospistg eistfgfs ondgsos fbefstsoive'i having been iadsvakiaisy pfeadsoíhéd sthfo AiT^T ^msdty. ®d· f^f^snrafiott·» fAtOO» ' HBvAg cosnpfex and AK'tOH - D-T-Pfxd-f1)A «orstpfey) die: conthsodd ikSíASdoiorsri a psspsmdiöo eoshprisapt she Ak κ.>11 tIBvAg-l1‘^tvd HiA so tyftfeh thd asrsosgsts ot eaefsidf the ofeotestts have:: beets oktsmsolo ohdsjn mmm. ehgvesgiosgdlT' irons 5 to 17 μκ ol HBsAg .·' dose; pseferahh i ft μ.> s dossh dons 20 to 40 Lf of D / doses preferably sVoos. 2? so 55 fSr slose; esgfroty pofesssfdy 30 Lf / dose (Lf- ifndS:ofiisteegferidn) (esgross^f5¾asvjfser t^as. «he sosooso «t ft »v ^catcr doto)> ihnn 3 to '25 Lí ot T ί ptxfershív note Rs k< K- Π dicse, ensiseSy pretetnhfy Rl k-f >' dose ieo-o'-sseO n ux'thóí oat, fsv ,s'TK'»u' .ν' Γ !.;·ί.ν.'ϊ úi -.i; ο' cOvoP *o 4ó U,' dosts), írom 20 ki Rs >rg oH'HA í ek>.x\ ps'to'es'ehh 25 ng / dose, *ÍO K'< 5 <\li \5 i\M ' C t. >>5> X ' '< » V ÍV; $lfi>t<li.ng to »oe particular embodiment of fh« invossisss, folio artiigeng, Which conveotteaMy #b:$lsí 01' s«,s''tsv'tmg v!í\! too -A„: addeo k t<o e-oooon>\l ϊο aed ρ-dnoüUí.>'\ o; ths t tspes mooíh, ps\?ou5 ** pdsasrit: vaccistess, i.e, types i, 2 ot 2,«? «lse, its the iísi ^sat ti would oof he accessary to vaednaie sg&htvt Ée-3 type». io introduce only she types agoinst which protection ts sought. The anwuefe ot pohovsms per dose ?ósy iu particular be betwee ^.u -»ΉΙ »V**'>t ' m' sp -o > 4b t' rcr\ \ ste..! ^ í'>i o Ot *s wtKi <' s miw between I? 85id 36 ídi, in particular >2, tor type >.
These antigens sf« not »?ce»»rity preadsorhed onto- an ahansnssm s&ii hetibe being addesl to she νρρϋ&$ prepát atKss. Λí. eosdissg so esn- punieutsr eosbsxlimesu. she nuohod aeeosding so the invention isti method wherein: (0 its) the TsUsÁg tssid ít*e AlOOH are brought into contact in ti)* ui veres of nssy other antigen* and:the JIBsÁg Is allowed to adssnth onto she AIOOH Tor »t ted 4 huurv, preferably «I least 12 boats, estfirofy nates e< \ eg" ^ n atyK house e-eh* nr spej station cwttsnn s»g <m Mi KB! HR Agv usrpSux; (;) ;b} .·, preparation comprising she 1. Pi'xs! and RiA antsgesis. prendsorhed onio AIOOH, soul optknusSK mkhsionol fieic&ioiVn p-.-nut^s antigens. such tss periadm surd aggSHttegans, is added-to rise pa \usd ό obkooed » vndps'h 0*> phosphate ioos a»v added 6> the jnepsfasion obtained in point {ss ib) in .order to. 1 :.Í.<^Í cesíoöskrassoss is>. the vaccine <0 4Í) tnMoM; (in) polio isoUgene ore oprioeshy added to the reeperetiois obtained sss point (ii): (iv) a pteparaiiott eotitaiithit: tiie Hth onitgen is added t» the preparsdion obsained inippmt (hr or |ssi|; (vj She pH e .uipi\5ed So ?.S ,:,4.1. as:d (vi) i<5! os least ooe caiiome amino »e*d is added so as ie eompiete she prepismtloo «Mated :id ssotnt i is 5 or {vss ixddo.' she adást I»» of the ΗΑ antigen, os' 'J>i at lea>s ten- iOSecec ososou as'sd :s added So sS.o shh áassi.en J vthoie at os k ^ leoe '4 s os st aü > u t ‘ »v ttn -. \ >o htdhe'vsssote os as less! 100 osg's.
Arcerdistg so -esc psrtkoior esvhodnsseist, hie sssOisisn· esiistposhson aceordsng h> the mventsitji x a ooisgsositiois cosnpsktnp ilissAg. dsphsheria torn· I), sessssms tócsa I', the Pl>.d end HIA ohooping ennejs ,οΟί.οί.Ο5 h&tsng SvCn pi .adsciS'Kd Oijso AiV'St it I 0"' t Sd' .-ns i' aO>\ OpO ssso S'- she pnhe -. ,ds :o,, O: v,' i,}, ikast''s a f ,<m>ohk <! , ' s to d >·ικ'.κν\ \ i-UV \g piwm s" h xosrp'\5t\ ' \ kv'ps noaostted on the AiOUH tor st 'east 3 «moths storing ttom tto' dote of snamtfacture <*f «he cítrajxrviissm stored nt & tempst'ottne of > * ,3 \.; ttod <n) iu least h$%, 70% <HAji*fcmMy 7500 of Jits loti! smtottni of t^:^:|^ípá pSÉtht' thltti:' «urapositioo is oos adsmisiioolfist AfOOH, ifps ^öüntf^amfftg isíkiivgp sísmoveí time. 5;s addhims by vntue of'ska method necordsssg h> iho mvmiiion, «ho antigens other «hart HBsAg tvhieh shooed that it was mivimmyeos^ for thorn to be adsorbed onto aiummasn oxide hydroxide in order to be aomiomgeoia, mm tiKo kept adsorbed. lbtiss ft jg indicated, by veny of exitmpfd ihnx & «ο«^Ι|Ι$η ftbdiÉ®g.fF'®^ fn^hiónhAfty sospprtsl::
IdiA f 0 to .30 pg of HBsAg /mi: preferably 20 pgdhtf;
Stom 00 to tiO fdot D'tnl, pretetithiy- from 50 u> 70 U o»iv tlhsn IBM SO Lf οΠ'/ms, preferably from 10 to 30 If óvd; from 00 to 00 na ut FHA ost; pmsersbo SO pp nth - finnt 00 u< 00 pp at f* fvd'mL mermaids 5tt pg mi, nmn 3 ut«ti ogof t'RPnti, psetesafdy 20-34 ugml; from i to .7 síig s> AR)í HHm pnAerahK I d mg of AiOOH nd. phospisao ;> '! s ,o o .oneustiudm* at 3? to o? snMoi * psetesabH from OS u> 07 nvMol 3 of phosphate sons; frosn 1 00 to i {300 pg'mi of cationic amh«> adds. prsAerabfy from 40# to 800 pgétni; and optional^ p,d {t>v!fo·; types i, 3 and 3 in hnsetlvated Aims, in n ivmxmtive amount of SO, 30 snd 04 DU/nd
As psevsoosiy üsdsaaíed, a oontpcenoon aecotding to the invention smsy also <.ompme adsition&i Bonh'fdk) l erfusih' aistsgeos, such S'- pertae.ms t<d 09 kDa) o« isgghnifiogcus. tkseripssoo of the tlporv ! igm, 5.- a vchen-a at s pssm mi u-eb-mi nm.ua; ,a, \n«e U earned smt aO-a -v addition of each component 3Ak01BlS tmiovts mhn'aie pteparstihm sd n hoik t2$d 5) <« * Ikpft 3.3s 3? AiOm« pdto Hill hexnvetesst xasoCihe 5 toe pteporation is ossned not undet .-tetiie emelmon - atsd v^ith «mOimams 'Sitrae:.
A Frppsratios of líBsAg sdsnrbísd onto AiOOH :A Mn'ii>g<s55e3At5t $«st%tsiofi of &iut»mom nxsde hydroode {AlOOHi gel -sold by .Bresnstag A03. «3 S g of niumissíümdi is introduced asoptscsUy mh>« SO I tanh.
A3fet ^stnejtion tfnotsgh a..o 32 rot' idtm she volume o3 RBsAg teotoreti m e'btnsn a wkentity#* of 30 ne *ot m the tbe;d viter ate ss eontsoaoissfv ndvkvstothr tajvh aiready eofitasmíjp she ARtOH t t'r ms'tort'm A it to its to* 30 m 7 3 iu««s ,0 ,,)s,hsent r, nt|V\4oso ;.o a< toobt,oa a homos mu o; s NOH-mneien B - )be§wsstftra οί 13 * 1' » IM'vO * Fi i Λ sdsörís^l »«U* »!««»»«*« gel h'i $vsr,:Ok-l, δ m; Ahfe os' aisimiíiisss* gel, diphtheria iwxokl (öt, tetsssas tossral * >). isordairihi portássá; Sftxoid ίΡΆΟΆ v v ι«» \! t*Mi' Ιϊ> ΪΧ ίϊ li S.J It! ' i í \) \ P V l'd» V ' ÜXs ''' Is A homogeneous· s«s^m!öo fjf AI0O? I gél. söi|i% brpddi #0, ht f g sr>so & 3501 tank d u > '0 ini h * Be* vj η>νΊ o e* V'Kv ss< < ' m^j'Kuí 0ts\ 1 t t v *hs »gx * i)' m,t >vi ! tin k Iíü1 v ! v »' Us Sk h X H'ü » u<k 1θ!>Ιΐ! ν*\ϋ\' j 1' >;<.'íh enUftüou» !« she ttraft xs»\'»no ut hO I f (hmsí ot ntKenkfton) mi .smi 00 I *-'mi O-kc *hc hóm*. &e neons >»'\λ v has Kva eb-a u*t Λ vustn'ivuon .ot ^UO |>»-«:«»L»Mtíeo.ont«,Ak>*2t* :«»«1 ife&v Őse suspension οΠ'ΗΛ preadsmbed <*m> AiOOH ere siseeíssivdv .iddi*£a«9tfoú& «ttferfti ksÉ* k »o)er:?o :í?hkk. PTM süni FliA .eoüppitatiohs in Ősé tip) vhpsftg:ef2f Bgmsl· $1#%, Οι* vohísfö dí :M ;s|M óípikptae hifiik· repfftM ίθί:01>0θί0δ Irtfó imlMgi/i i$ Aided sOin* (iiísdfko thtoggh s 0.32 piti ipftBx i! , í!v í \ , Π \ * kd, ". i'vosw'ri ss tód s<:>sls·' fos- at lead 14 hours at a ísm^xsíííU$re oí5 t :);>C.
Γ - Prepanstmu oí the rass-tiire ot HBsAg t 0 ♦ T * f FBA lie ^νί,Μ a so* v«s δ 0 apes»' % a a hk\ »< ptm t s ‘ > he vSASsft.><.ns>KaiKd >>s s.s>sm b 1 h s \t te is k0 to -sí! a ' χ{ δ ΐ} a eg- \ v s m spension, !he volume of $<K> mM phosphate bs;!T»t seipilreii ΐ·.> obtahs a phftspj'i;sie; sfts> eoiU^!!stebi5h :0f 4fl :S3klO:l3l in the Oha! ftomptsitson ;s Slsets adtlftti after ftjfrftiiosx shsoiish a 0.0.2 ura fsbes·. 13 - S&tso'fttiöu ot the eleetrostelk sites ut she attsmssutsis gel ItOsAg * l> * ? -s FIs si e I it Λ .eemjrée* wttfe a solution ofoutino acids A solution stfissTSisso adds eontasmng i 2 essesstisS sussisxo aeOSs. having she tollowing cftss^ieslit^hx^F^ft^®^·· - Argmsrse hyvIroehios'sOe .,.0 1 g/i, i.ft; ).75 g?iftíhígkifte • C>SSÍtK: ......);2 g/i - Hbikke ..,,s,,Mm, 0A g;i
·>:. |:|ti|ftíip|áft' , - < : ν::ϊΐ:':>Χ'ΐί:: 2 6 gO
- j.endue..................... 2,6ψ I - bysise .hydrochlwkie.. 3.65 go, he. 25) I. g,d of lyske - Methionine............ 0.75 p/l - I'heuMvikonne . .. 1..65 g-i -%-mötsiöe.,;·..;.............. 2.4 g/i - Trypínfskan ·.< ·,:, vV.,.,. y.,,,.,. 0.4 gd ·· lyraxine ! Jgd :-- ¥fc,,.....,,,lip
Thai k k< ss»\ 3 5 v* g.d d^atnlno·a«"y& toe.U«dWfc 5,44 g··i os'utionk amino *ckh <H«v Arg - Lyx}.
-On* ' S v *t x H> i ^ *» S ,!<» ^n>< Kiih 0 , ‘ ft'K with stimog iw Id be 11¾ amino MÜÜ sAifenvilBi^^iiKrosJgk a 8.22 pm filler w cotusmtousty tokkal k> the mixture obhihsed hffe m m··k?: PbfA 3:gooeegkatkoyof -|f|-pgtitI of estlnpip amino aeida In the 8M;t^mpsíjkm, K -- pH Adjissfsrtent S x rU or ms suspenxtenropimtted *« posm » J "U'i I ' -Ogu' u\iiv * * ‘sodium hvdroskSeni2.5 N. k -- Addition of the pofin atifigopi -&:.preparation eopigpuog ppltovitm xerotypes i. - and > ut inactivated form «.Mahoney* I and Saohett xti-gpis, rssspeetsveiyl iMiered through a 0-24 pm filter. is shea introduced into th« Sank comamutg the suspension obtained in E.
C - Addition of PRF T
An smermads&te «.ohmon -d' ERE- Γ is tirsi of ad prepared in ibe foHrwmg wav; Trlx-mcro-sc bush-.-:. fdtervd ^forehand through :s <U2 pm filter. is added to a preparaiku? ofPRJM' filtered through a 0.22 pn? fdlsr. so as :iseorumsitse an mte« mediate mi More. S'fds i* infiod'iMNi weptsoaUv m«o ski. 'mentre otmm-'\i in S', H - hinat adjwMtmmtpteie \lt! VI I «<, < (. d |ac i J\|V is OS WO vl i «< « <>' fOnlpt. iifp e. ui OSiM.A Ά * i< Vida, ι <i in seuee dii' t&tuet vySame ni i'd s s«. added. I he». » sexessan, Use pli «r «ρν m-xiure is adjusted ín pH 7.1 j. is.: hy adding a nreíikered 2.5 id sodium hydroxide or kt% acetu: amd solution. T he mixtme A stored id ? ;- ;V <; inén d'xt< ibn'ed smo i»yr>oges or honk;. m a p»op<>i Oon nf Ú 5 od do -'
Ode: d.5 nd dose dnn. eogiaisk kOd ggof A= :ih i 0 ug of Η'ϋχΛκ, no ipsa than Μ Η i of D, m k*s* than 40 M.f of Ti lS gg of fs, 25 gg of i-HA, between >8 mtd 43 Dii {D anttgeo o«hs) of poito type I, between 5 anri 0 i >s s of poiks tyf-e 2, between i? and id DU of polio type 3, VI ug of VfiP (in the fortn of i'RF- f). phosphate ions a- a ekhkenSraiKni of 40 MMnkl Tris-iaetoi.e hnSor at a uoneemnssion of 2.5 roMol/l of fris anef or 2 t :?.55W-of· sucrose, arid nko aao ug oi i.atn>nie ..orbno η-,'χΐχ sd us -- Arg -· 1 .y-.,,-. klithkaldridl;:
Ilte vaccine contpnssthm ptapami oceenitog: i&ihvmm%$k above w^tósá^-a^llateaí *rlah eompreddfea hexctvaient vnccin© aiteady pteaent oo Ahashttckeí, vttddrett against the same diseases as tbc y atomé ptepoted aeeotsJmg ío &»st»ve«t3ao. whooping sxmgix politx Hih ntfeetkmc a«d hepotttw B^ bsx wblebíbssib líssífeölar the drawbackthst o pstst sí $ is iyophiiized and therefore nxtsxstes on operáltat) to take sgs Ahes Ippbsbsibs |5s’i<'!' to the sdsnAAtsStsa sproeedtae. tSoHhgdfr t't««Kv' «rxn. tk ' vu e* ofv^* « x - ^npoeotottv were· ottoWibrdííf^.tfi s wssethesohosos; cwsipSfsthg lidíWhs ddtöhitsisíed 0É3!$ attá b sooaths. Thei .lápod. vaobioe prepared s8«<^éis§.-M-:iií8:5s»attioá,:ot· ihe· invention proves* fo be vers welt federated. ami as o«t»»»ö|ostfeas the vsaésbs prsssbtíssss thomorkeo
hXi^RlMENI Ab DATA
Fereeotage astsssrptiOS of íJB* Ag/amoxoxt of oosmhxorbod FÜí^T
Thíps hawhosóf ihat bxdk product (Pb V3$*4l~12> ^tWfe:S^^oh^áiS^iÍJ«teáint#tófe::|I:11^34I)···”' alf the hsabhes haváig 'bge».:ebtaxsed sasordbxgm d)s easn»|ile provided - were stored at : 5*C and «?«%·:·>*;! at wsricssx* sím®s sverw psíMfMFF -and 22 motets*, the^stseo^tMia^ioh· of HBsÁ;gaís#:f:hs ooxsoíh^
The percentage adsotptkm of the VIBvAg *as dstomdaedpas- was pstídbasly Mieat<?át ttom the tótat liBsAg; extent ana the noxxadsorhed BBsAg mwmi tbs mtb-»s%g:s:sas^feh Π IS A method no-cording to tlx· shies defined by the laioipto-ifiraeia^sta^itvb Bt#%* tho f !B«% was captured h> an asht-MBsAg prim s v tao ><. s o * dthex, of h>M t> f> > sw b of « *»h west pitxe t ne UBc \>>. this hwiiii was Mated: Aftthüáa anti-HStóg 'sm^k^monoeiöt^a^ii^yj o^ip:'ií^· whísh wtor hsssh' detected hy means of-tsg^őaidasss«ö^fed atü||P :p^eS*rt8Í: :a»Ülitoáy< Á: lahwapphte. :s8hs?tste tor tpsroxkhisib í«,U:o»»<".rt>1benaiöine tTMÖ), sx-t veá-as· «-dewloplog agmt>: Pheo It was aháetb s ooIöe· dé¥etope4 tho intensity of wttteh was p^Htríional to the amotim of HBsA| oaptoraslia ithe wolh 1:'he: sesoka: wore; 5 !ÍW( >d> the M! twuu W Vfi\'S XX ÍO^í ü!KO \ ^ to order ίο dcteíiflioe the percentage ad-ioqdiotí oí hie Uíb;Ag. she vnacíse was eohncleh to <í-'n-;rifngst>oa ,^gpO g; 5 mf\; 20VCX which made il pocink ;<ϊ íoceoer the supernatant contain mg ttse nooads-wbed HBsAg. S be saovgias oisopemahmts to he tested were mhaed so t i tS.A hotter eosoprssosg a dea^rpttoo hssOer, in 2-sbld sedal oiithion» in a «attge incHtdext. for «sample, Ixdweest Β40ΰ οίκ1 tíb> ht>d, jt O SX SXi V ΐ Ú f * iti h ¥> * >1 s I ^ \ Ί ^ e't onv'gft ts s'i 1 ! ! t i dí#lá;sátM IbliÉsat»^ hetwoeis l/ü.gnd
;A ih-wels sdsie coated whh the pitmttsry nscote-'toosti tssitshn-.ty was mcotsated hw \2 h as AC and then washed svith is PBVTween ah cotsososx Use ctihshcasa >s' she syp^nafasxts, <>t stse total varessw and oftlte sssassdssoj range wese dsso'sdmed inio the weha The sr-xasthwy asohx?dy woe then added anditte developing oos estrried oos with :t!?- xu s t ^ i ο,! v ϊ |x d >s,v< 1 tresnsO c 1 eoesAw) «V v sv x·- t>s xsd* < S H€t itefte was 3Ö wíh ?lí« #!§*
Iwee» 2ö sobdoo. A IMró '(áieített baí&f} .3» .mtó«á. te·: Λ» ρΛΛ: weUi. «hkI oí^ws^t. ito is&me PÉmaxav The pkse wasMáaí 00 4li «S $M 88¾..
The sammoR of ííiosadsoAed RRIM' wss svalosssefe fey HPÁBC-TAD (high pmfmmm®· mim spfesop «shmsnaíöifsphiyio:pdskíl delsefeoo} I» iho;Édlö»lo| ^sp á siásdassl raep :öfím&rsa«e i BE.P*T of ISA fe> ÍZS.^míwmfmt of#U fnspnsá 1¾ snipes to Be fessed· sssi sise lhe-stasiiaoiiraoge ssmpip smo eeooifeípd as SOfKí g for Λ min as smfe-em :iap^ÉBsl: Tho soprossMix :wer& eolhssfed ásd diós hy&tiágz®$:, wdSi:3: ,h$ N NaO h»1uUo« conMining ghjeosasíios'· S->phosphaSe as mlsnsd ss&odarö. A felsők p<R% M8C| tM ki -M&Qlí -r intvrml α&βώαά) λκν Silded.
The eferomaiogt&phy sv&s csnied mt wdh a moldle phsss composed oí 3 5 mM NnOI I and I i4 öíM öl sodmm acs-ate, i'ojéxaed inio the eofesmn as a nde cd I 2 sol/oss. í^iMasÉlph# WM»rii£iq0H${ (Boriké ««.* of the PRP peak * sütik* »tm f f: |PIP cookíksiRidl i-hw· wfeki !ía;í ís she slope and "b" i% the hpjpgf bps llhs. fesi»«í.
Üss<%sörfstk?osteef btsbíhthe ^iBáAgeös'síamöílp hitéé hlfehéTőfuhat bhtbpaehaef (FÖhiS-tfccse bMéis^-BiÉBbyíéggntíí hohley ζβ 44-45-4¾¾ ef u;ik|U|4 0bp4ibtiös eeippibeh4441)4: s$$M miigm&fak ofammém^ráfag fa a jihélit heSöathtá 4 pptri áip| BSsfgftip BíBImít !Ms that destahheá itt the esaiepie Φί>$% «&$ abohesiesi This pte|5afh|lás eMbihéiT ifi 0.5: tál: iÖ:kj| öflIlsAg, 3Ö Lf öttHi SÜ Lf öf 44, 31 μρ öf Bt, 2Sp|eof FÍ4A, 4h DO fif fgtttávihfis typé l, |: t)Ü et poiiiJVii'uS Cvgá 2, 32 011 ní'pohövtnss type 3, 15 pg »C;PBh0o the ibris sí FhfF-T), Ö..fi sfig öf A!, fihöáfiháíe Ihat át a eöséesttfMsás öíbá ntMoMitsafitonafe ions et a sííataetítítóeo of 30 iskfót/i, Tab-suetese bhfíht át a éefiefeéfiMkíh éf TSpMoi/l with tespeet to Tab: and 2454% with respeot to etweese, ásít 14 fig. ítf eatíösb gfiühfi sekis (hEs: --- Ábp - Bys) oHghsaítog trónt the Mi 44 m«4iam.^íio"val808«)» gB 4.4 - 4,4 , lltstessiB obtained were the íiEkswsng:
The aíráemss ot noondborbed EÉF-4' íseasateá over the saste peaksg showed that: ihere wfis khíe: vá$áik>fi eosspared wish Esne tg ;sk! were therefore saEstaeiery,:. jHówéyers these re&uifö, show :ti?$h is ihb eáhe, Mfish
Claims (2)
- does ns>t corfVstptvid te a ínefnühniOü sA'ismed hy vessz rd a maisod zs ixnvhng to the snveníjsHo tns- uepsishg B SzSidttev KitdgCSX did Oot r'ertuiiü iidssüsod Ott thst .Steossem OXsie OS sls'Ostsie. Experimental tinta relating to the c;ma«h: amino tieids Λ cs'-n-posilion according to the invention resokitig directly írom die expó'. intendő ptotocol cacti esi oat in ate ex ample provided arid a composition obtained by vn'toe. of a ptorovsn tnodiited in thai a composition csmtalnisg only the three eaitotbe amino acids (Arg · t.ys ·- HH) bad been *Bbtfi!t*f<l for the composition of the id essen! tat atom» as ids vvete esnopartrei o itb teg&td to she nomtdvortsco amoom sit t hi - s at the cad, oio ctols-re m e h* the amount of oonadsorhed PkP-i oso observed, thereby soroséig that only the eltörne amirv acids are important. i. i.djhm folyékony oUbanysigdtomfeírűelö eiMiitusáta, amely tartalmaz legalább ,d»mhmmi td-hkii'O'sidse kAiOOft';. vs heistOftsz fl Svl\, ss etCigCist $He,4p\ cv >! s » < » . s* χίίι'Ί aiders, at s v hotdnmk * pd-v hot ,η-h κ<ρ ndst-s pofesaeksBttiiiS till, alsói a..:h«|pfe« Bi fels^at aiiigdh AfCXdlbh adsmdioafva yah, rotg a Msb antigén net» asizeieva VaOt:: ahol - a hepbife B iisgihi tat igára AKX>Brs suBzxirbeáijuK, Hy módon AiOOSbHBsA|ykompiexet kapunk, a AtiXdnilUAg'B-'iorb'v legalább tt»t> no; : ksma'aou >0m Uinmos •m-ms-as s-s l'' mMott koncemskiciójó idsztitkm jelenlétében ósszsásívs-sji.ik a Hit! antigénnel. 3, Á® li igénypont szerinti eijaraa ah»! a HBsAg antigén AiOOkhiznszpenzió ás BBs.-Up'sUi.szpsmzio ispiMhb 4 drln kcreszitii történd kövemével s;g» teaekeverésévd vsa as tdundmomra sdszorbcátvs. .5, A?, i ias-isspotii szérián eljárta, shot a HBsAg antigén AiOOB-'-eosepeneso ás lIBsAg^wisrpeozio : e i i ·.!>" | '· , g g,^s s'»te· o's t I' <do sWsrae t issna* diám mii d » hs\tB h. Az i igénypont szérián epriig ahol a IIBsAg antigen AiGOJi-s/nsspenrid ás 11 Λ-srersí:p*íieit> 'lögáiúhh 30· 34 Órást keresztül tdrtenh ke veresd ve·! vald ósszeketetésávei van u *mmt«H?rora ad»zorbeálvü. n ,\f igénypontok. bármelyike szert ri ή eijarás, s23.nl jeliemmé, hogy a kát ionos enenosav a Mib ghtigennel t«tUNU> íkvvs-ks venB ehm van ne AlOöH/HBsAg· komplexhez adva. n az i vágj a 3. igénypont szerinti eij.tr.B, azstüt loilemezveg .bstgy a katiöstos aatimsjav az. AiO= >H ; n. \ -\*>" 'kwJ '0 i\s- SüvStvis t ΐ b stg^nk' A4 7. \s eie/<' u'án'Penis'v sarí!>...'hike ízért Ό en-ees, gzzat jelhatozve, mgv <* k^zlht-uo e Bt"· üntigébhel történd ó^zaktrwrás elsMt van »z AIÖÖH/HBsAg-komplexhez asivst. 8·. A;í döA> igénypontok bármely ik« ta»«nti djára*·, »tml jribmetM* hegy az AiOOH/DBsAg-kunmlexeí tótóltoéöy ι»Η-> * Hife tmmb asvtkovews dbu \1*0,I énekre san beáiigYÖ. %s i „e ' o\ ήϊ i c· v* **«0! MUme*'·*· »> o ios>. \ ' I <. < \ 'As - tegdább égy* dBMns-, mmUM-t pdtkfc· & si^máfköiH^ésAMA»#» kftcBi vátesaiotf aseiseml és Ms!tv&|AnK>Kkkhkk<;xkk>5 tartalmazó kéaxítmány előállítása, &> az AIO0H/HBsAg-*ompl«s bssaekeMíféss· a kí*xttmén»yek a ΠΒ> aitilgéonel történd összekeverés dóti. Λ U* ! ,íhrΆ --,¾ί ίϋ ,Sí - ,η üü'fisl idUste^e leg' * kníe\ \mv! > j kevrtoa'ro doAs''kíní !' HÍ. π V π<. ,'kOgn! . iV-Art kín Cvó by <Ti<.hvOy: UbUViÍíiU0V^N^'h«1nkV.vkx.tUa.;^)\'SÍ>l«E:,í és keveréssnl mindegyiksoJigémlKi:í,z.á3eés közbe. U. Ac I. igénypont sjwrinti-eljfcfe, asual.j«limi'*ve, hogy tartalmazza a következőket: - 3 BlksAgmik az AÍÜOlt «senny igenek egy sészére történő aősaorfeeáiási*· ««ely a γέρο ké-Aoodíyben sdemévö ísíísí, AKKbli egyb&nnsdn. dKB oráe ketesztök Ily niődon ΛΚΧ.Η0Ή B.;Ag'komplex • pAtim/amo**» a következők egymást kővető adtoArbeáláaa egy további AkXSR'mtsmyiaégre:' difebheovm (Dk Eídonisnobo i'Ti, Bi'-rJstetiü í'wrtif&'ii*· tisztított tözinja íPT-Híi); amely R5aga.:p?eads;sörbeáiv&: AiÜOB-m, és B&-<lcttiiie fiUna'nitwus hemagglutinin (FHA), amely maga pt^tóasbifeálva vm AvV1! i iO i .. O be '. < J Ά^! iiií .V XkMjB. IP Ά, XO V Λ w epéx A - tbíszfStionok ho/z&aláui olyan e»«fty>*égb<m, amely tehetővé teui a végső késM$»48fl^8'"4ö. ffiMiiM koncemrtk;«dérévé;, - tvgaiabb eg) k«t Ionos amesosav höz.?áatteaa olyan mennyiségben; amely lehetővé issd a· végső késíiliíH s'sben legalább JÖÖ mgö koncemraciö «térését*. - a el í bed leess d Idi,1 ertbkn, - ^olkesfíligének hozzáadása maktsváfi íimtáptan, * ailisb .set igén hozzáadása, - a pH bed ihass 7,1 dl,; értékre. < ss v>rtk>srtO·' lí. -(crtos lás' b^suaiom. \ s «. ain^kbi ti! A?, eiöso igéoypoorek bénoebAp szirtijei eljátáj.. a.sral jsliesa'sve. Ia>gy legalább .7>0 I isbónovog-ks-'s'inen> ke··.Ad rgen mertékoen B, OH»km).ag-késziiméjsy, «πκΊ> az eíbrti igenyponOik !>ám*rty»ke szermb dekami vas» eiőáiHÜW^.'is. u>iJMi/.rt b'gsBrtb s begs,íi.sz J5 ebem: sebvéni v}ütsAe) λ a sbb aert^ot aossiyej Jesanjjvriehéijébez 'köJsjegáis poilrlbo/énbeoe fon/rás alkot. bl Az vlo/b igessypo’d sreroiti olKaevag készeotóex azzal p-ikesezvé, bpgy: tsrlsiéísa:: tlíftemn. ítemM.Sk>5 pobe- 4§ skMekkdhbgns-sfitjgéol h. 15. A 13. vsg> bi igiíeypooí <®amu oitóanyag-kásalsmény. aszol jellemmé bogy mrf&imam· bpláldk - a heoatisisz. Is ieiszml síglgéek HbsAg-t. - a diíiériaaebgdi} tiiftéíusíosle (i.í.s femeekhaiy a íekeoisz.oaigéíst Ka&oussloxle (Ti :l>te4jábaeS; ,s ti>OP 0**8*1> fíksSXU'aíAítíS Μ軣*Σ*«»»ν pN$) ÍÖSTRÍp' l»5Si .:f»jrm#N«k ~ si polk>&f5(sg£oek«( 1, 2 <5« 5 íipusl»H3 vá i;ms ok in ski ;vál( v i su-s RsrmpisHi. ' o \ U W5 n\ ^ho«r>v((gU't,'!i(5Ci"s «*osl itfkmxxs* 8*>*(v kiosdrs VisS^h - 10--3(5 Mg H.BsAg-t KiilHHfcrrasakeak - 40-8(51. f B?i piOf teöí&áOk - ;0-:K>i.r r-í!«jliülí«et5ké(ik - 40-60 og FHA-t mimiltereokííO, - 40-"í*FI ví~t •lüSOOx-ftnkí'ni, -:--60 y« OROo tmihh&renfccnk PRO-r-kkftjagsUBR - *ng Λ MOH - msOsfsMa ski's - .53-45 reMökml fos&Oiou!. - H)0-:0UO sr>g,0 kaík-ixo aHo«öS3v<j(. - s--s:s. .?-«>. «s. ,5-uá Opusa poSiovOast is',<fkssv;\U k>wuáb&!k S’Skáro ffi). .16 és 04 DEúnf íMOSfíSsé^^- 3 7. A 18. igén) ps.>nl ssermlt olídmy»^·ke><0««én>, ra*»I hogy l&ípmuMopIPte - 0(5 Mgknl BfesAg-k - -(5-70 1 1 i(0 D-í, MMOU/m; r-k - SO MgOssi ΓΉΑ-4 - 40 Mg/íík 0 lAO-f 0 >' j ís s5f M > ingák? > t sPtkiik í ' - 5.5 >s;g/s'íi5 AK.K 01-5. - '13.4;: mMoik íbszfáliosk - 400-808 msy'l kutlmsos &iyeks>say.4, - j-si..
- 2-es és 3-55.S lípusú poHovImt 5rsí^kliváli R(rmá4>«í>? gstsdte:1 lS ésE>333ssΪ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1250464A FR2985663B1 (fr) | 2012-01-17 | 2012-01-17 | Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE032539T2 true HUE032539T2 (hu) | 2017-10-30 |
Family
ID=47714410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE13704171A HUE032539T2 (hu) | 2012-01-17 | 2013-01-17 | Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására |
Country Status (34)
Country | Link |
---|---|
US (1) | US9358294B2 (hu) |
EP (1) | EP2804628B1 (hu) |
JP (2) | JP6199310B2 (hu) |
KR (1) | KR102019848B1 (hu) |
CN (1) | CN104039348B (hu) |
AP (1) | AP2014007848A0 (hu) |
AR (1) | AR089737A1 (hu) |
AU (1) | AU2013210927B2 (hu) |
BR (1) | BR112014017416B1 (hu) |
CA (1) | CA2861304C (hu) |
CR (1) | CR20140356A (hu) |
CY (1) | CY1119206T1 (hu) |
DK (1) | DK2804628T3 (hu) |
EA (1) | EA026058B1 (hu) |
ES (1) | ES2625011T3 (hu) |
FR (1) | FR2985663B1 (hu) |
GE (1) | GEP201706642B (hu) |
GT (1) | GT201400120A (hu) |
HK (1) | HK1204293A1 (hu) |
HR (1) | HRP20170692T1 (hu) |
HU (1) | HUE032539T2 (hu) |
IL (1) | IL233643A (hu) |
LT (1) | LT2804628T (hu) |
MX (1) | MX349411B (hu) |
NZ (1) | NZ627345A (hu) |
PE (1) | PE20141515A1 (hu) |
PH (1) | PH12014501546A1 (hu) |
PL (1) | PL2804628T3 (hu) |
PT (1) | PT2804628T (hu) |
RS (1) | RS55962B1 (hu) |
SI (1) | SI2804628T1 (hu) |
UA (1) | UA113000C2 (hu) |
WO (1) | WO2013107988A1 (hu) |
ZA (1) | ZA201405431B (hu) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
WO2021176409A1 (en) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Preservative combination for vaccine composition |
KR20230173114A (ko) | 2021-04-20 | 2023-12-26 | 케이엠 바이올로직스 가부시키가이샤 | 6종 혼합 액상 백신 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ283910B6 (cs) * | 1992-05-23 | 1998-07-15 | Smithkline Beecham Biologicals (S.A.) | Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku |
US6790445B1 (en) * | 1997-02-06 | 2004-09-14 | Merck & Co., Inc. | Preservatives for vaccines |
ATE470434T1 (de) * | 1997-02-06 | 2010-06-15 | Merck Sharp & Dohme | Thimerosal-freie konservierungsmittel für impfstoffe |
AU4707097A (en) * | 1997-09-15 | 1999-04-05 | Pasteur Merieux Serums Et Vaccins | Multivalent vaccines |
WO2003009869A1 (en) * | 2001-07-26 | 2003-02-06 | Chiron Srl. | Vaccines comprising aluminium adjuvants and histidine |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
EP1414433B1 (en) | 2001-08-07 | 2006-04-12 | Laboratoires SMB SA | Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
FR2828406B1 (fr) | 2001-08-08 | 2005-06-24 | Aventis Pasteur | Composition vaccinale bivalente havi |
GB0610140D0 (en) * | 2006-05-22 | 2006-06-28 | Insense Ltd | Protein stability |
PE20100366A1 (es) * | 2008-10-24 | 2010-05-21 | Panacea Biotec Ltd | Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion |
-
2012
- 2012-01-17 FR FR1250464A patent/FR2985663B1/fr active Active
-
2013
- 2013-01-16 AR ARP130100131A patent/AR089737A1/es not_active Application Discontinuation
- 2013-01-17 SI SI201330643A patent/SI2804628T1/sl unknown
- 2013-01-17 BR BR112014017416-4A patent/BR112014017416B1/pt active IP Right Grant
- 2013-01-17 CA CA2861304A patent/CA2861304C/fr active Active
- 2013-01-17 LT LTEP13704171.1T patent/LT2804628T/lt unknown
- 2013-01-17 HU HUE13704171A patent/HUE032539T2/hu unknown
- 2013-01-17 KR KR1020147022200A patent/KR102019848B1/ko active IP Right Grant
- 2013-01-17 EA EA201491387A patent/EA026058B1/ru not_active IP Right Cessation
- 2013-01-17 RS RS20170449A patent/RS55962B1/sr unknown
- 2013-01-17 US US14/372,695 patent/US9358294B2/en active Active
- 2013-01-17 AU AU2013210927A patent/AU2013210927B2/en active Active
- 2013-01-17 PT PT137041711T patent/PT2804628T/pt unknown
- 2013-01-17 EP EP13704171.1A patent/EP2804628B1/fr active Active
- 2013-01-17 UA UAA201409180A patent/UA113000C2/uk unknown
- 2013-01-17 DK DK13704171.1T patent/DK2804628T3/en active
- 2013-01-17 CN CN201380005797.8A patent/CN104039348B/zh active Active
- 2013-01-17 AP AP2014007848A patent/AP2014007848A0/xx unknown
- 2013-01-17 PE PE2014001091A patent/PE20141515A1/es active IP Right Grant
- 2013-01-17 PL PL13704171T patent/PL2804628T3/pl unknown
- 2013-01-17 ES ES13704171.1T patent/ES2625011T3/es active Active
- 2013-01-17 NZ NZ627345A patent/NZ627345A/en unknown
- 2013-01-17 JP JP2014552680A patent/JP6199310B2/ja active Active
- 2013-01-17 GE GEAP201313552A patent/GEP201706642B/en unknown
- 2013-01-17 WO PCT/FR2013/050106 patent/WO2013107988A1/fr active Application Filing
- 2013-01-17 MX MX2014007850A patent/MX349411B/es active IP Right Grant
-
2014
- 2014-06-19 GT GT201400120A patent/GT201400120A/es unknown
- 2014-07-03 PH PH12014501546A patent/PH12014501546A1/en unknown
- 2014-07-14 IL IL233643A patent/IL233643A/en active IP Right Grant
- 2014-07-23 CR CR20140356A patent/CR20140356A/es unknown
- 2014-07-23 ZA ZA2014/05431A patent/ZA201405431B/en unknown
-
2015
- 2015-05-26 HK HK15104967.4A patent/HK1204293A1/xx unknown
-
2017
- 2017-05-10 HR HRP20170692TT patent/HRP20170692T1/hr unknown
- 2017-05-31 CY CY20171100571T patent/CY1119206T1/el unknown
- 2017-08-23 JP JP2017160109A patent/JP6356886B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL245365A0 (en) | ATP-linked cassette transport modulators, pharmaceutical preparations containing them and their uses | |
HUE025694T2 (hu) | Fokozott stabilitású folyékony fenilefrin készítmények | |
WO2008063910A3 (en) | Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions | |
HUE032539T2 (hu) | Eljárás legalább két, alumínium-oxihidroxidra adszorbeálódni képes antigént tartalmazó oltóanyag elõállítására | |
WO2005035514A3 (en) | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups | |
UA91815C2 (ru) | Выделенное антитело, которое специфически связывает gdf-8, и его применение | |
NO20082530L (no) | Imidazopyraziner som proteinkinaseinhibitorer | |
WO2005021022A3 (en) | Stable formulations of peptides | |
WO2006136162A3 (en) | Tuberculosis vaccines comprising antigens expressed during the latent infection phase | |
MX2017010945A (es) | Preparacion solida. | |
WO2008021076A3 (en) | Protein matrix vaccines and methods of making and administering such vaccines | |
WO2005009381A3 (en) | Immediate-release formulation of acid-labile pharmaceutical compositions | |
WO2003076603A3 (en) | Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions | |
WO2006066914A3 (en) | Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors | |
WO2006014962A3 (en) | Liquid stick antiperspirant | |
US9078824B2 (en) | Composition and method of stabilized sensitive ingredient | |
WO2005115414A3 (en) | Orally-administrable compositions comprising stable amorphous calcium carbonate | |
WO2005016264A3 (en) | Diamine derivatives of quinone and uses thereof | |
CA3156494A1 (en) | POLYOL RESIN BLEND FOR USE IN THE PRODUCTION OF STABLE POLYOL COMPONENTS | |
MX2007013327A (es) | Formulaciones de liberacion prolongada. | |
WO2009080764A3 (en) | Oral or nasal administration of compounds comprising amino acid sequences | |
WO2008099835A1 (ja) | Peg充填硬質カプセル剤のバンドシール | |
AU2003273473A1 (en) | Novel substituted pyrazolo(1,5 less thanigreater thanaless than/igreater than)-1,3,5-triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same | |
MXPA05010613A (es) | Formulacion parenteral de acido micofenolico, una sal o profarmaco del mismo. | |
NZ741552A (en) | Compositions and methods for treatment of homocystinuria |